Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

12. november 2026 oppdatert av: Cugene Inc.

A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion

Studietype

Intervensjonell

Registrering (Antatt)

65

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • NEXT Virginia

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed and dated informed consent.
  2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
  3. At least 1 measurable lesion according to RECIST v1.1.
  4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
  7. Life expectancy of ≥3 months.
  8. Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.

Exclusion Criteria

  1. Rapidly progressing disease or disease requiring urgent alternative medical intervention.
  2. Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
  3. Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
  4. Concurrent participation in another interventional therapeutic clinical trial.
  5. Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
  6. Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
  7. Unresolved clinically significant toxicities from prior anticancer therapy.
  8. Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
  9. Active or clinically significant infection except as specified in the protocol.
  10. Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
  11. Known hypersensitivity or significant allergic reaction to biologics or its components.
  12. Recent vaccination, except as permitted by the protocol.
  13. Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part A Dose Escalation

CUG279 will be administered at multiple ascending dose levels

CUG279 will be administered intravenously according to the protocol

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of dose limiting toxicities (DLTs)
Tidsramme: From the first dose up to 21 days post-dose

The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A.

From the first dose up to 21 days post-dose
Incidence and severity of treatment-emergent adverse events (TEAEs)
Tidsramme: From first dose through 90 days after the last dose

The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of serious adverse events (SAEs)
Tidsramme: From first dose through 90 days after the last dose

The number and percentage of participants with SAEs will be assessed.

From first dose through 90 days after the last dose
Clinically significant changes in safety laboratory parameters from baseline
Tidsramme: From first dose through 90 days after the last dose

Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Tidsramme: From first dose through 90 days after the last dose

Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in vital signs from baseline
Tidsramme: From first dose through 90 days after the last dose

Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of TEAEs leading to dose modifications
Tidsramme: From the first dose through the last dose; up to 1 year

The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed.

From the first dose through the last dose; up to 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum observed plasma concentration (Cmax) of CUG279
Tidsramme: From first dose through 90 days after the last dose

The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Trough plasma concentrations (Ctrough) of CUG279
Tidsramme: From first dose through 90 days after the last dose

The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose

From first dose through 90 days after the last dose
Area under the concentration-time curve (AUC) of CUG279
Tidsramme: From first dose through 90 days after the last dose

The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data.

From first dose through 90 days after the last dose
Terminal half-life (T1/2) of CUG279
Tidsramme: From first dose through 90 days after the last dose

The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Systemic clearance (CL) of CUG279
Tidsramme: From first dose through 90 days after the last dose

The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Volume of distribution (Vz) of CUG279
Tidsramme: From first dose through 90 days after the last dose

The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 antibodies (ADA)
Tidsramme: From first dose through 90 days after the last dose

Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Tidsramme: From first dose through 90 days after the last dose

Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined

From first dose through 90 days after the last dose
Objective response rate (ORR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Disease control rate (DCR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Time to response (TTR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1

From the first dose through study completion or until disease progression; up to 1 year
Duration of response (DoR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year

Time from first documented CR or PR to disease progression will be determined per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Best overall response (BOR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year

Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Progression-free survival (PFS)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. november 2026

Primær fullføring (Antatt)

30. mars 2029

Studiet fullført (Antatt)

30. mars 2029

Datoer for studieregistrering

Først innsendt

19. oktober 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CUG279-P101
  • IND 179862 (U.S. FDA IND) (Annen identifikator: FDA)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere